P500 Post-marketing safety experience of vedolizumab in patients receiving concomitant treatment with other biologics

類似資料

• Post-marketing experience of vedolizumab: Pneumonia and other respiratory tract infections
  著者:: Bhayat, F, 等
  出版事項: (2017)
• Post-marketing safety experience of vedolizumab in older patients with inflammatory bowel disease
  著者:: Travis, S, 等
  出版事項: (2018)
• Post-marketing experience of vedolizumab in inflammatory bowel disease: analysis of pneumonia and other respiratory tract infections
  著者:: Bhayat, F, 等
  出版事項: (2017)
• The safety profile of vedolizumab in ulcerative colitis and Crohn's disease: 4 years of global post-marketing data
  著者:: Cohen, R, 等
  出版事項: (2019)
• Incidence of pneumonia and other respiratory tract infections with vedolizumab treatment: clinical trial experience
  著者:: Feagan, B, 等
  出版事項: (2017)